跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ADLYXINE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ADLYXINE
Authorized
STANDARD
ADLYXINE
sanofi-aventis canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
560b63607e5960dc
Company
sanofi-aventis canada inc
Type
Standard
Approval Details
Approval Id
560b63607e5960dc
Drug Approval Canada Name
ADLYXINE
Product Name
ADLYXINE
Status
Cancelled Post Market
Status Date
2018-10-08
Original Market Date
2017-09-12
Din
02464349
Drug Class
Human
Dosage Form
Solution , Kit
Route Of Administration
Subcutaneous
Schedule
Prescription
Ahfs
68:20.06
Atc Original
A10BJ03 LIXISENATIDE
Atc Name
a 10 bj 03
Aig Number
0259130001
Company Name
sanofi-aventis canada inc
Company Address
1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4
Active Ingredients
LIXISENATIDE
0.05 MG / ML
LIXISENATIDE
0.1 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
560b63607e5960dc
Type
Standard
Back to Health Canada Approvals